Wednesday, August 18, 2021

Session 1: DTA Mutations
Moderators: Maria E. (Ken) Figueroa, University of Miami, Miami, Florida and Ravi Majeti, Stanford University, Stanford, CA

Sessions 1 and 2 Introduction
Ravi Majeti

*Dnmt3a* mutations in clonal hematopoiesis
Jennifer Trowbridge, The Jackson Laboratory, Bar Harbor, ME

*TET2* mutations, inflammation-induced plasticity, and myeloid transformation
Iannis Aifantis, New York University Langone Medical Center, New York, NY

*ASXL1* mutations in clonal hematopoiesis
Ravi Majeti, Stanford University, Stanford, CA

Session 2: Non-DTA Mutations
Moderators: Maria E. (Ken) Figueroa, University of Miami, Miami, Florida and Ravi Majeti, Stanford University, Stanford, CA

Mechanisms of clonal competition in the context of PPM1D mutations
Margaret A. Goodell, Baylor College of Medicine, Houston, TX

Spliceosome mutations in clonal hematopoiesis
Esther Obeng, St. Jude Children’s Research Hospital, Memphis, TN

DTA vs. Non-DTA Panel Discussion
Moderators: Maria E. (Ken) Figueroa and Ravi Majeti
Panelists: Iannis Aifantis, Margaret A. Goodell, Esther Obeng, Jennifer Trowbridge
Thursday, August 19, 2021

Session 3: Clonal Hematopoiesis and Non-Blood Cancer Consequences
Moderator: Benjamin L. Ebert, Dana-Farber Cancer Institute, Boston, MA

Session Introduction
Benjamin L. Ebert

Clonal hematopoiesis and risk of cardiovascular diseases
Siddhartha Jaiswal, Stanford University, Stanford, CA

Clonal hematopoiesis and infection risk: Correlations and complications
Kelly L. Bolton, Washington University of St. Louis, St. Louis, MO

Deciphering and targeting clonal hematopoiesis
Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, NY

Session Panel Discussion
Moderator: Benjamin L. Ebert
Panelists: Siddartha Jaiswal, Kelly L. Bolton, Ross L. Levine

Session 4: Population-Level Studies of Clonal Hematopoiesis
Moderator: Maria E. (Ken) Figueroa, University of Miami, Miami, Florida

Session Introduction
Maria E. (Ken) Figueroa

CHIP in elderly twins: Concordance, discordance, survival, and epigenetics
Kirsten Grønbæk, Rigshospitalet and BRIC, University of Copenhagen, Copenhagen, Denmark

Population studies in clonal hematopoiesis: Hematologic malignancies
Pinkal Desai, Weill Cornell Medical College, New York, NY

Clonal hematopoiesis and risk for cardiovascular disease: Insights from population-based studies
Pradeep Natarajan, Massachusetts General Hospital, Boston, MA

Session Panel Discussion
Moderator: Maria E. (Ken) Figueroa
Panelists: Pinkal Desai, Pradeep Natarajan

Panel Discussion
Clonal Hematopoiesis: How Do We Design Clinical Trials and Approve Drugs?
Moderators: Ravi Majeti, Stanford University, Stanford, CA and Maria E. (Ken) Figueroa, University of Miami, Miami, FL

Panelists
Benjamin L. Ebert, Dana-Farber Cancer Institute, Boston, MA
Kelly L. Bolton, Washington University of St. Louis, St. Louis, MO
David Steensma, Novartis, Cambridge, MA